铝镁匹林片（Ⅱ）治疗稳定型缺血性心脏病的作用及不良反应

Abstract
Figure/Table
References (23)
Related Citation (0)

Download: PDF (356 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To evaluate the effect of Aluminum-Magnesium and Aspirin Tablets (Ⅱ) on the platelet aggregation function and gastrointestinal reaction for stable ischemic heart disease. Methods A total of 587 patients with stable ischemic heart disease requiring Aspirin and Clopidogrel dual antiplatelet aggregation treated in the Department of Cardiology, the First Affiliated Hospital of Chengdu Medical College from January 2015 to May 2016 were selected. They were divided into A, B, C group. 195 cases of group A were treated with Clopidogrel, 196 cases of group B were treated with Aspirin and Clopidogrel, and 196 cases of group C were treated with Aluminum-Magnesium and Aspirin Tablets (Ⅱ). The platelet aggregation rate, efficacy before and after 30 days′ treatment, incidence of adverse reactions were compared among the three groups. Results The platelet aggregation rate after 30 days′ treatment of the three groups were lower than that before treatment (P ＜ 0.05). After treatment, the platelet aggregation rate among the three groups were statistically different (P ＜ 0.05). After treatment, the platelet aggregation rate in group A was higher than that in group B and C (P ＜ 0.01); while the platelet aggregation rate had no difference between group B or C (P > 0.05). The treatment effect of all groups of anginas had no statistically significant difference (P ＞ 0.05). There was no significant difference in the incidence of cardiovascular adverse events among the three groups (P> 0.05). The incidence of gastrointestinal adverse reactions was lower in group C than that in groups A and B (P ＜ 0.05). Conclusion Aluminum-Magnesium and Aspirin Tablets (Ⅱ) has good clinical efficacy in patients with stable ischemic heart disease, and have fewer gastrointestinal adverse reactions.

Key words： Aluminum-magnesium and aspirin tablets (Ⅱ) Aspirin enteric-coated tablets Stable ischemic heart disease Platelet aggregation

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Lu CHEN Lin ZHOU Peng

Cite this article:

LI Lu CHEN Lin ZHOU Peng. Effects and adverse reactions of Aluminum-Magnesium and Aspirin Tablets (Ⅱ) on stable ischemic heart disease[J]. 中国医药导报, 2018, 15(29): 58-61.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2018/V15/I29/58

[1] 金九如，魏丽萍.参麦注射液与左卡尼汀在治疗缺血性心脏病心力衰竭的优势分析[J].中华中医药学刊，2015， 34（5）：1265-1267.
[2] 郭秀丽.氯吡格雷与小剂量阿司匹林对胃黏膜损伤的对比研究[J].中国医药指南，2016，14（17）：181-182.
[3] 张永珍，高炜.稳定性冠心病诊治策略的选择：欧美指南给我们的提示[J].北京大学学报：医学版，2014，46（6）：832-835.
[4] 沈迎，张奇，沈卫峰.美国和欧洲稳定性冠心病诊治指南解读[J].中华心血管病杂志，2014，42（1）：70-72.
[5] 唐伟良，彭放，王兴祥，等.阿司匹林、氯吡格雷和华法令三联抗栓方案在冠心病治疗中的应用[J].中国动脉硬化杂志，2012，20（10）：956-960.
[6] 万德立.硫酸氢氯吡格雷与阿司匹林联合治疗稳定型心绞痛的效果分析[J].中国当代医药，2018，25（3）：108-110.
[7] 郭艺芳.双联抗血小板治疗进入个体化时代?——2016年ACC/AHA冠心病患者双联抗血小板治疗指南解读[J].中国循环杂志，2016，31（2）：84-85.
[8] 徐德亮.氯吡格雷与小剂量阿司匹林对胃黏膜损伤的对比研究[J].中国临床实用医学，2014，5（4）：46-47.
[9] S?覬rensen HT，Mellemkj?覸r L，Blot WJ，et al. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin [J]. Am J Gastroenterol.，2000，95（9）：2218-2224.
[10] Juul-Moller S，Edvardsson N，Sorensen S，et al. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris [J]. Lancet，1992，340（8833）：1421-1425.
[11] 张澍田.阿司匹林和氯吡格雷所致胃肠道损伤的防治策略[J].中国实用内科杂志，2011，31（5）：336-337.
[12] 黄岩，樊朝美，黄一玲，等.复方阿司匹林抑制心血管病患者血小板聚集的24周疗效[J].中国新药杂志，2011， 20（7）：613-615.
[13] Hachiken H，Murai A，Wada K，et al. Difference between the frequencies of antisecretory drug prescriptions in users of buffered vs. enteric-coated low-dose aspirin therapies [J]. Int J Clin Pharmacol Ther，2013，51（10）：807-815.
[14] 胡君茹，姜华，刘效栓.阿司匹林联合氯吡格雷抗血小板治疗的研究进展[J].中国药房，2013，24（8）：750-753.
[15] 刘东涛，贾伟华，周立春.阿司匹林与氯吡格雷抗血小板聚集作用效果观察[J].山东医药，2014，54（46）：74-75.
[16] 杨雅薇，李攀，陈韬，等.四种氯吡格雷抗血小板功能检测方法的比较[J].第二军医大学学报，2016，37（8）：1002-1006.
[17] 周丽雅，张静.亚太地区非静脉曲张性上消化道出血专家共识意见解读（五）：非甾体类消炎药、阿司匹林和氯吡格雷的使用及不良胃肠道事件的预防[J].中华消化杂志，2012，32（3）：148-149.
[18] 许春奇，尚亚东，程仁力，等.氯吡格雷、阿司匹林和辛伐他汀联合首剂负荷量治疗老年急性脑梗死的效果[J].中国老年学杂志，2017，37（17）.
[19] 李强.冠心病患者应用氯吡格雷引起的抵抗发生率及其危险因素[J].中国当代医药，2016，23（7）：35-37.
[20] 徐岩鹰，周恕敏，吴军.氯吡格雷对非ST段抬高型急性冠脉综合征患者血小板聚集率的影响及近期临床疗效观察[J].河北医学，2016，22（12）：1937-1939.
[21] 黄岩，樊朝美，胡大一，等.镁铝匹林抑制血小板聚集的Ⅱ期临床研究[J].中国新药杂志，2007，16（24）：2066-2068.
[22] 苏强，唐志立，杨思芸，等.汉族PCI患者CYP2C19基因多态性与氯吡格雷抵抗相关性研究[J].中国药师，2016， 19（3）：424-427.
[23] 林孟娴，周燕琼，翁燕丽.心脏介入术围手术期预防用抗菌药物干预效果的回顾性分析[J].药物流行病学杂志，2016，25（1）：38-42.